Walker MS, et al. – Researchers undertook this investigation to measure efficacy outcomes and patient reported outcomes (PROs) in a community oncology patient sample. They observed that bevacizumab–containing regimens were related to longer progression free survival (PFS) and overall survival (OS) compared with non–bevacizumab regimens. PRO measures showed disease progression was related to worsening health related quality of life (HRQOL). They suggested that delaying disease progression can sustain better HRQL and lessen symptom burden.